Member Info for Quickdraw18

PAH00 may i ask are you the type of investor who only reads good news and views?

PAH00 I was replying to:

"Odx’s market cap would consist of more than just Covid test revenue?"
Food Intolerance sector Also ???

Would the upfront fees be disclosed be booked if booked last yr.

"Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million"

Question'a what's the upfront fee? Doest seem a massive amount for a suggests game changing tech. Will Affimers manage to one up anybodies in LFT's? What about therapies?

Would say avacta are past hopes, hence they are wishing a new agreement with Mologic delivers them some success. Started development in April and what do avacta have to show for themselves?

What happened to:
Avacta & Cytiva - saliva S Gene LFT
Avacta, BBI & Abingdon - Nasal S gene LFT
Who to blame, who to trust?

Avacta & Mologic - S Gene and N gene test

Here's what's really happening. Graham's beautiful face and our cute Q's within this article.

Sequencing to last at least 10 yrs, so says Prof Pea**** of Cambridge Uni, who is charting at NovaChat on 26th

We know who's tests Cambridge use

While some companies will struggle and fail to detect the new mutations, SNPsig is all over it

Chinese new year, brings good fortune to the wise genetic detectives and innovators.

A must read for all covid investors

https://www.bioworld.com/articles/503479-covid-19-test-makers-are-adapting-for-variants

Do Abingdon have a antigen LFT test to produce now it looks like the Avacta LFT is done? Hopefully they get a 3rd party supply deal like ODX. Lower margins but at least don't have the stress of depending on own developments

Novacyt began the surveillance program when there were just a few hundred reported SARS-CoV-2 sequences. Now 308,000. #NCYT continues to review them each week. #ALNOV is working with a global network of virologists, tracking variants to identify mutations as they are reported

first three SNPsig assays enable the identification of the original strain of the virus, the U.K. (B.1.1.7), South Africa (B.1.351) and Brazil (B.1.1.28) variants, as well as any new variant carrying the N501Y mutation

"from what we know today, both the antigen RDTs & the majority of the molecular diagnostic tools are okay,” Carmona said.

“There are some PCR-targeted solutions just to detect those mutations, but those would be mostly confined for research and monitoring emerging variants.”

#Novacyt
"recently launched a PCR genotyping assay portfolio to detect COVID-19 variants. Based on the analysis of single nucleotide polymorphisms (SNPs), the SNPsig portfolio is designed to run on central laboratory systems on the company’s q16 and q32 rapid PCR systems"

https://www.bioworld.com/articles/503479-covid-19-test-makers-are-adapting-for-variants

“primary challenge for COVID-19 diagnostics companies is ensuring their products continue to accurately test for the virus, regardless of the variant, and to innovate at the challenging pace required to remain clinically relevant,” Graham Mullis, Novacyt

Novacyt’s dynamic innovation model enabled them "to keep track of new SARS-CoV-2 variants in real time as they arise and, as a result, continue to analyze our assays to ensure they remain able to detect the virus with the same high level of accuracy"

https://www.bioworld.com/articles/503479-covid-19-test-makers-are-adapting-for-variants

“For routine diagnostics, what you need to know is do you have COVID or not? And for that … most manufacturers [of molecular tests] have learned from the past that you need multiple sites that serve to use as your targets for amplification,” he said. For the antigen rapid diagnostic tests (RDTs), the majority have both a capture and a detection antibody to a nucleocapsid protein, and most of the current variants of concern affect the spike protein.

“So, from what we know today, both the antigen RDTs and the majority of the molecular diagnostic tools are okay,” Carmona said.

RDT=LFT
https://www.bioworld.com/articles/503479-covid-19-test-makers-are-adapting-for-variants

As of 10th feb 2,011,014 antibody test run by UK gov.

Flat rate of 120,000 pillar 3 antibody tests since the 6th of July.

Do we expect Abingdon to be awarded an antigen manufacturing contract like ODX?
https://coronavirus.data.gov.uk/details/testing

Looks like both companies benefit from the deal. With ODX getting a direct deal to make whatever tests the UK gov approves. Maybe ODX have moved away from the Mologic test and Avacta and Mologic have decided to combine their respective S and N gene research and developments to date.

"The partnership between Avacta and Mologic also provides a framework agreement for the future development of a pipeline of tests in a range of disease areas. The possibility of combining Avacta's spike antigen test with Mologic's nucleocapsid antigen-based technology[2] in a single lateral flow device is already being explored. A hybrid antigen test such as this is expected to be a world first and has the potential to deliver an extremely sensitive lateral flow coronavirus antigen test"

So just need to wait for clinical evaluation "Clinical evaluation of the lateral flow test" via "a hospital in mainland Europe and the Company will shortly initiate further clinical validation studies in the UK and abroad"

Promising RNS
https://www.lse.co.uk/rns/AVCT/commercial-partnership-with-mologic-g2zjd7jhz488cm0.html

Thanks for the share. Good to see Avacta are planning to working on a new combination S and N gene test with Mologic. Utilising all that Avacta have learnt this past year developing their Spike protein and Mologic's N gene test.

"The partnership between Avacta and Mologic also provides a framework agreement for the future development of a pipeline of tests in a range of disease areas. The possibility of combining Avacta's spike antigen test with Mologic's nucleocapsid antigen-based technology[2] in a single lateral flow device is already being explored. A hybrid antigen test such as this is expected to be a world first and has the potential to deliver an extremely sensitive lateral flow coronavirus antigen test"

https://www.lse.co.uk/rns/AVCT/commercial-partnership-with-mologic-g2zjd7jhz488cm0.html

Clear where the value is:

. Up to 8m LFT a month end April
. Gov lent equipment
. So discounted margins
. Retained value?

"intention is that as soon as the DHSC has access to a test that has successfully passed a performance evaluation, the test will be licensed for Omega"

Novacyt & ODX head to head:

#NCYT design, manufacture & sell OWN tests
2020:
Rev - £277m rev
Sales growth - 2,030% +
Cash - £92m cash
EBITDA profitability - £187m
Market Cap - £580m (2.09 x sales & 6.3 cash)

#ODX after 12 months don't have own test, aim to manufacture for unknown company. What happened to Mologic?

2020:
Rev - £7.5 sales (£9.5m assume inc funding)
Sales Growth - 19% -
Cash - £5.5m > £6m
P&L - £2.1m > £2.3m Loss
Market Cap - £167m (22.2 x sales & 29 x cash)

Hello everyone

Talk of us accepting COVID is deadly:

"In each warm body it infects, the virus behind Covid-19 has the potential to change. Most of those changes are slow and inconsequential. But, in some people, the virus hits the jackpot.
That is seemingly what happened in Kent in September 2020"

https://www.wired.co.uk/article/chronic-infection-uk-coronavirus-variant

There's a political view to behave and chose to react and accept the risks. Where scientific advice vs actions taken are not always aligned! The virus does not care for politics or public opinion.

103 years, penicillin & Vaccines required to flatten this Curve spanish flu / influenza.

Can't think there are many COVID sceptics on here. Imo as profiteers of the virus it's the least we can do to communicate and educate when we can.

Not a fan of investing death porn but this graph :-( Ain't over until the world defeats COVID

https://twitter.com/DopeinkInvest/status/1359667151708299266?s=19

Most of you will be happy I'm going to close the blinds on my ODX posting for few days. Shame no one fancied discussing any of the technical points i raised. After all i provided quotes and links to back up every statement

Never mind, I'll be back with audio clips from the ODX investor call from the 28th October.

You can argue against King Collins own spoken and written words. Imo the real juice is in spoken word.

Remember said no need to raise more funding to expand capacity to 2m a week. Let's see if he's true to his word

https://www.investormeetcompany.com/investor/meeting/trading-update-investor-presentation-1

Yes Gman and i've been clear on the ODX board what my motives are. Is a tragedy for PI's to be selling Novacyt a company who have delivered 10 COVID products this yr to buy shares in ODX, or even worse Abingdon who have a failed antibody product in a failed market (1,100 anybody tests in UK, flat lined).

And is a shame for investors to be buying Abingdon on the back of what seems like Avacta's flawed Affimer LFT antigen and hopes and dreams resting on your new agreement

Especially on the back of the revised gov Antigen LFT guidelines issued on the 8th.

No shorting by me, no need to, awful way to make money. But am not above being a white night in dark armour. Sitting on a heap of tragic UK diagnostics news I've been quietly collating since August/September. There is another that shall remain nameless until i do some more research.

https://www.lse.co.uk/ShareChat.asp?ShareTicker=ODX&share=Omega-Dia&thread=3CA8D73D-CF55-43CD-8A9D-BC5DC7DC4640

I don't own Abingdon are you mad

Thank you for the support Jimtom and for taking the time to read my comments on ODX board.

I've been clear on the board what my motives are. Is a tragedy for PI's to be selling Novacyt a company who have delivered 10 COVID products this yr to buy shares in ODX who have a failed antibody product in a failed market (1,100 anybody tests in UK, flat lined).

And is a shame for investors to be buying ODX shares on the back of LFT antigen hopes and dreams. Especially on the back of the revised gov Antigen LFT guidelines issued on the 8th.

No shorting by me, no need to, awful way to make money. But am not above being a white night in dark armour. Sitting on a heap of tragic UK diagnostics news I've been quietly collating since August/September. Would also not want to own Abingdon or Avacat. There is another that shall reman nameless until i do some more research.

https://www.lse.co.uk/ShareChat.asp?ShareTicker=ODX&share=Omega-Dia&thread=3CA8D73D-CF55-43CD-8A9D-BC5DC7DC4640